Study details
Enrolling now
NVG-291 Trial for Spinal Cord Injury
NervGen Pharma
NCT IDNCT05965700ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1/2
Target enrollment
40
Study length
about 2.7 years
Ages
18–75
Locations
1 site in IL
What this study is about
Researchers are testing NVG-291 in people with spinal cord injuries to see if it improves communication between different parts of the brain. The trial will also assess how safe and well-tolerated NVG-291 is, looking at physical exams, vital signs, and lab tests.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take NVG-291
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Secondary: Incidences of Treatment Emergent Adverse Events (Safety and Tolerability)
Body systems
Neurology